Table I.
Prognostic value of PPIA mRNA expression in different datasets determined by PrognoScan.
| Dataset | Cancer type | Endpoint | Corrected P-value | COX P-value | HR (95% CI) |
|---|---|---|---|---|---|
| GSE31210 | LUAD | Relapse free survival | 1.58×10−10 | 2.98×10−11 | 455.47 (74.93–2768.73) |
| GSE31210 | LUAD | Relapse free survival | 1.36×10−10 | 4.44×10−11 | 395.74 (66.79–2344.72) |
| GSE31210 | LUAD | Overall survival | 2.10×10−06 | 1.94×10−05 | 191.57 (17.18–2136.01) |
| GSE31210 | LUAD | Overall survival | 4.05×10−05 | 3.09×10−05 | 159.62 (14.68–1735.14) |
| GSE9893 | BRCA | Overall survival | 0.001131 | 0.000161 | 0.83 (0.75–0.91) |
| GSE13213 | LUAD | Overall survival | 0.001964 | 0.000172 | 2.55 (1.56–4.15) |
| GSE13213 | LUAD | Overall survival | 0.001602 | 0.000288 | 2.46 (1.51–3.99) |
| GSE4922-GPL96 | BRCA | Disease free survival | 0.000787 | 0.00043 | 6.99 (2.37–20.65) |
| GSE8894 | NSCLC | Relapse free survival | 0.011737 | 0.000637 | 3.50 (1.71–7.19) |
| GSE1456-GPL96 | BRCA | Relapse free survival | 0.013126 | 0.000821 | 7.41 (2.29–23.98) |
| GSE8894 | NSCLC | Relapse free survival | 0.020635 | 0.000857 | 3.36 (1.65–6.85) |
| GSE1456-GPL96 | BRCA | Relapse free survival | 0.006499 | 0.001082 | 7.12 (2.19–23.09) |
| GSE4922-GPL96 | BRCA | Disease Free survival | 0.002932 | 0.002276 | 6.07 (1.91–19.34) |
| jacob-00182-UM | LUAD | Overall survival | 0.041268 | 0.002379 | 0.46 (0.28–0.76) |
| GSE11121 | BRCA | Distant metastasis free survival | 0.01496 | 0.003358 | 17.39 (2.58–117.31) |
| GSE17537 | COADREAD | Disease free survival | 0.008844 | 0.004248 | 0.01 (0.00–0.20) |
| GSE9195 | BRCA | Distant metastasis free survival | 0.008393 | 0.004407 | 29.78 (2.88–307.85) |
| GSE26712 | OV | Overall survival | 0.004054 | 0.004925 | 0.20 (0.06–0.61) |
| GSE4412-GPL96 | LGG | Overall survival | 0.036877 | 0.004997 | 8.47 (1.91–37.66) |
| GSE9195 | BRCA | Distant metastasis free survival | 0.024659 | 0.00592 | 26.26 (2.56–269.20) |
| GSE3494-GPL96 | BRCA | Disease specific survival | 0.047207 | 0.008505 | 6.92 (1.64–29.27) |
| GSE3494-GPL96 | BRCA | Disease specific survival | 0.002599 | 0.009594 | 5.69 (1.53–21.20) |
| GSE4412-GPL96 | LGG | Overall survival | 0.000433 | 0.009663 | 7.34 (1.62–33.25) |
| GSE4573 | LUSD | Overall survival | 0.0207 | 0.010494 | 5.57 (1.49–20.73) |
| GSE1456-GPL96 | BRCA | Disease specific survival | 0.006336 | 0.013111 | 5.75 (1.44–22.92) |
| GSE2658 | Multiple myeloma | Disease specific survival | 0.034132 | 0.013804 | 2.29 (1.18–4.44) |
| GSE13213 | LUAD | Overall survival | 0.012258 | 0.014126 | 2.17 (1.17–4.02) |
| GSE26712 | OV | Disease free survival | 0.008361 | 0.016461 | 0.29 (0.11–0.80) |
| GSE13213 | LUAD | Overall survival | 0.021354 | 0.018883 | 1.94 (1.12–3.37) |
| GSE19234 | SKCM | Overall survival | 0.002576 | 0.019303 | 209.26 (2.38–18399.93) |
| GSE13213 | LUAD | Overall survival | 0.012258 | 0.022418 | 2.07 (1.11–3.86) |
| GSE19234 | SKCM | Overall survival | 0.002576 | 0.023501 | 151.59 (1.97–11682.11) |
| GSE17537 | COADREAD | Disease free survival | 0.006344 | 0.024266 | 20.40 (1.48–281.27) |
| GSE17537 | COADREAD | Disease free survival | 0.009107 | 0.026693 | 18.60 (1.40–246.70) |
| GSE13213 | LUAD | Overall survival | 0.011179 | 0.031871 | 1.83 (1.05–3.17) |
| GSE2990 | BRCA | Distant metastasis free survival | 0.030163 | 0.044086 | 5.10 (1.04–24.91) |
LUAD, lung adenocarcinoma; BRCA, breast invasive carcinoma; NSCLC, non-small cell lung cancer; COADREAD, colorectal cancer; OV, ovarian serous cystadenocarcinoma; LGG, brain lower grade glioma; SKCM, skin cutaneous melanoma; HR, hazard ratio; CI, confidence interval.